Stock Financial Ratios, Dividends, Split History

CENX / Century Aluminum Co. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)1,455.85
Enterprise Value ($M)1,288.64
Book Value ($M)830.40
Book Value / Share9.48
Price / Book1.75
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Weighted Average Number Of Shares Outstanding Basic 87,295,000
Common Stock Shares Outstanding 87,544,777
Common Shares Outstanding 87,562,526
Weighted Average Number Of Diluted Shares Outstanding 88,020,000
Scoring Models
Piotroski F-Score4.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.06
Return on Assets (ROA)0.03
Return on Equity (ROE)0.06
Balance Sheet (mrq) ($M)
Quick Ratio1.21
Current Ratio2.88
Income Statement (mra) ($M)
Industrial Revenue Bonds7,815,000.00
Sales Revenue Goods Net391,004,000.00
Sales Revenue Net1,589,080,000.00
Revenue From Related Parties1,198,076,000.00
Operating Income93.86
Net Income48.58
Earnings Per Share Diluted0.51
Earnings Per Share Basic0.51
Cash Flow Statement (mra) ($M)
Cash From Operations51.76
Cash from Investing-17.36
Cash from Financing-17.36
Identifiers and Descriptors
Central Index Key (CIK)949157
Related CUSIPS
156431958 156431908

Split History

Stock splits are used by Century Aluminum Co. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

21h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Related News Stories

Earnings Confirm Alcoa Corp Is in a Sweet Spot | InvestorPlace

2018-04-19 investorplace
Alcoa Corp (NYSE:AA) has posted its numbers, and the first-quarter earnings season is unofficially underway. And, if the company really is the tone-setter for earnings reports, we have good reason to be excited.the aluminum company topped its earnings expectations, and AA stock advanced 4% in response. (120-0)

Aluminum Stocks Jump on Trump Sanctions

2018-04-09 247wallst
When President Trump threw Rusal CEO Oleg Deripaska under the bus last Friday, commodities traders and investors began to calculate how much damage the Russian aluminum giant would suffer. The answer appears to be “a lot.” (54-0)

Something Just Isn't Adding Up In The Recent Data

2018-03-17 seekingalpha
The week started off strong out of the gate on Monday in the wake of Friday's post-payroll rally, but the momentum quickly faded, leaving the S&P 500 down four consecutive days as of Thursday's close. If it closes in the red again Friday, it will be the longest losing streak in over 16 months going back October 31st, 2016. We dug into the details of the recent data, and in this week's edition, we point out some things that just aren't jiving. (109-3)

Has The Aluminum Bull Market Come To A Skidding Halt?

2018-03-16 agmetalminer
Aluminum buyers are understandably nervous about the future price direction following the near-9% fall in prices from a high in early January. (37-0)

Do 3 Fresh Analyst Upgrades for Century Aluminum Signal the All-Clear?

2018-03-14 247wallst
Century Aluminum Co. (NASDAQ: CENX) is one of the great American metals companies that should be set to win if steel and aluminum tariffs do not turn into an all-out trade war. There are of course risks, particularly if steel and aluminum were just the start. Wall Street thinks Century Aluminum is now in the sweet spot. (13-0)

CUSIP: 156431108